logo
World-first gonorrhoea vaccine launched by NHS England as infections soar

World-first gonorrhoea vaccine launched by NHS England as infections soar

Yahoo21-05-2025

England will be the first country in the world to start vaccinating people against the sexually transmitted infection gonorrhoea.
It will not be available for everyone. The focus will mainly be on gay and bisexual men with a history of multiple sexual partners or an STI.
The vaccine is 30-40% effective, but NHS England hopes it will reverse soaring numbers of infections.
There were more than 85,000 cases in 2023 – the highest since records began in 1918.
Gonorrhoea does not always have symptoms, but they can include pain, unusual discharge, inflammation of the genitals and infertility.
How many people will chose to be immunised is uncertain.
But projections by Imperial College London show that if the jab proves popular then it could prevent 100,000 cases and save the NHS nearly £8m over the next decade.
Max, a sexual health campaigner, told BBC Newsbeat he would "100%" take the vaccine after being diagnosed with gonorrhoea twice within a year.
"I think this is great that it's been announced", he says, adding: "It's going to take the pressure off the clinics, it's just a big win all round."
Vaccination will start in August and will be offered through sexual health services.
Public Health Scotland said it was also working on plans to launch its own programme for high-risk individuals.
BBC Newsbeat has asked health bodies in Wales and Northern Ireland whether they intend to do the same.
This vaccine wasn't designed for gonorrhoea. It's the meningitis B vaccine currently given to babies.
But the bacteria that cause the two diseases are so closely related that the MenB jab appears to cut gonorrhoea cases by around a third.
That will require a delicate conversation in sexual health clinics as the vaccine will not eliminate the risk of catching gonorrhoea. It is normally caught while having sex without a condom.
But Prof Andrew Pollard, the chair of the Joint Committee on Vaccination and Immunisation (JCVI), which recommended the vaccine, said despite it only being 30% effective, it was "worth having" and could have "a huge impact" overall.
The decision is not just about the record numbers of cases. Gonorrhoea is becoming increasingly difficult to treat.
Most cases are treated with a single dose of antibiotics, but there is an 80-year history of the bacterium which causes gonorrhoea repeatedly evolving resistance to our antibiotics.
It's happening to the current treatments too and is why some doctors are concerned gonorrhoea could one-day become untreatable.
The best way to deal with a drug-resistant infection is to never catch it in the first place.
Dr Amanda Doyle, from NHS England, said: "The launch of a world-first routine vaccination for gonorrhoea is a huge step forward for sexual health and will be crucial in protecting individuals, helping to prevent the spread of infection and reduce the rising rates of antibiotic resistant strains of the bacteria."
The people most affected by gonorrhoea in the UK are those aged 16-to-25, gay and bisexual men, and those of black and Caribbean ancestry.
The vaccine – which costs around £8 per dose – is value for money when primarily offered to gay and bisexual men, rather than all teenagers.
However, clinicians do have the freedom to use their own judgement and offer the vaccine to people using sexual health services they think are of equally high risk.
People will be offered mpox (formerly known as monkeypox), HPV and hepatitis vaccines at the same time.
Potential new antibiotic for treating gonorrhoea
Don't ditch condoms, sexual health experts say
Prof Matt Phillips, president of the British Association for Sexual Health and HIV, said: "This is excellent news and a landmark moment for sexual health in England.
"Gonorrhoea diagnoses are at their highest since records began and this has the potential to help us to turn that around."
It is not known how long the protection provided by the vaccine will last or how often booster jabs might be required.
The decision comes almost a year and a half after a vaccination programme was recommended by the UK's JCVI.
Sexual health campaigners had criticised that long wait, but have welcomed this decision.
Katie Clark, head of policy and advocacy at the Terrance Higgins Trust, called it a "huge win".
Listen to Newsbeat live at 12:45 and 17:45 weekdays - or listen back here.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Women on blockbuster weight loss drugs warned to use effective contraception
Women on blockbuster weight loss drugs warned to use effective contraception

Yahoo

time2 hours ago

  • Yahoo

Women on blockbuster weight loss drugs warned to use effective contraception

Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.

Women on blockbuster weight loss drugs warned to use effective contraception
Women on blockbuster weight loss drugs warned to use effective contraception

Yahoo

time5 hours ago

  • Yahoo

Women on blockbuster weight loss drugs warned to use effective contraception

Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.

Diabetes Status May Not Affect Outcomes of Preventive PCI
Diabetes Status May Not Affect Outcomes of Preventive PCI

Medscape

time5 hours ago

  • Medscape

Diabetes Status May Not Affect Outcomes of Preventive PCI

The PREVENT trial found preventive percutaneous coronary intervention (PCI) combined with optimal medical therapy was more effective than medical therapy alone in reducing major adverse cardiac events in patients with non–flow-limiting vulnerable plaques. The new analysis found patients with non–flow-limiting vulnerable plaques had similar 2-year cardiac outcomes regardless of diabetes status, but those who received preventive PCI combined with optimal medical therapy had lower rates of cardiac events than those who received medical therapy alone. METHODOLOGY: The post hoc analysis of the PREVENT data compared the clinical outcomes of preventive PCI plus optimal medical therapy and medical therapy alone in patients with (n = 490) or without (n = 1116) diabetes. Plaques were defined as non–flow-limiting when the fractional flow reserve was > 0.80; vulnerable plaques were identified using intracoronary imaging. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction, ischemia-driven target vessel revascularization, or hospitalization for unstable or progressive angina at 2 years after randomization; the median follow-up duration was 4.3 years. TAKEAWAY: At 2 years, the incidence of the composite primary endpoint was not significantly different between patients with diabetes and those without the condition (1.8% and 1.9%, respectively; P = .956). = .956). The composite primary endpoint occurred less frequently with preventive PCI than with optimal medical therapy alone for both patients with diabetes (0% vs 3.7%; log-rank P = .003) and those without diabetes (0.5% vs 3.2%; log-rank P < .001). = .003) and those without diabetes (0.5% vs 3.2%; log-rank < .001). The reduced incidence of the primary endpoint with preventive PCI was mainly driven by reduced rates of ischemia-driven target vessel revascularization and hospitalizations for unstable or progressive angina in both patients with diabetes and those without the disorder. IN PRACTICE: 'These findings support that preventive PCI…irrespective of diabetes status, in patients with non–flow-limiting vulnerable coronary plaques,' the researchers wrote. Vulnerable plaques 'may be guilty by association but may not be the sole culprit behind residual cardiovascular risk,' wrote Diana A. Gorog, MD, PhD, of Imperial College London, London, England, in an editorial accompanying the journal article. Such plaques 'may be just one marker of a vulnerable patient, but not the only determinant of risk. Perhaps we need to find better ways of identifying the vulnerable patient, rather than focusing solely on vulnerable plaques,' Gorog added. SOURCE: This study was led by Min Chul Kim of Chonnam National University Hospital in Gwangju, South Korea. It was originally presented at American College of Cardiology (ACC) Scientific Session 2024 and was published online on May 29, 2025, in European Heart Journal . LIMITATIONS: The clinical outcomes were exploratory as the study was powered only for the composite primary endpoint, with event rates lower than anticipated. The researchers did not differentiate between type 1 and type 2 diabetes, which might have limited the generalizability of the findings. Intravascular imaging at follow-up was not performed routinely. DISCLOSURES: This study was funded by the CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx. Several authors reported receiving research grants, consulting fees, and honoraria from various pharmaceutical and healthcare companies, including the funding agencies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store